secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001193125-26-054797
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics regains Nasdaq compliance on minimum bid price requirement
------------------------------------------------------------------------------

- Received Nasdaq letter on Feb 17, 2026 confirming compliance with Listing Rule 5550(a)(2).
- Had been non-compliant since Feb 21, 2025; deadline extended to Feb 17, 2026.
- Met requirement by maintaining $1.00+ closing bid for 10 consecutive trading days through Feb 13, 2026.
- Common stock will continue listed on The Nasdaq Capital Market without interruption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526054797/0001193125-26-054797-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526054797/atos-20260217.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-054797

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer